What research findings exist for Retatrutide in obesity and weight loss?
Obesity combined with type 2 diabetes patients showed improvement in weight and blood glucose control at 80 weeks. Other studies reported significant weight loss in obese adults; Specific knee osteoarthritis and sleep apnea subgroups also showed improvement.[1] ↗ [2] ↗
Currently, 4 original studies related to the theme of this page have been selected. The number of studies includes different designs, populations, or preparations, not commercial clinical efficacy ratings. This page is a usage-oriented positive data selection, not a systematic review or dosing recommendation. Historical studies, combination preparations, and special models are all separately indicated.
Comparison of study design and results
Results from different populations, species, materials, or follow-up times cannot be directly combined. The table below is a comparative summary of published data, not new experimental data.
| Literature | Study subjects and design | Observation and discovery | Scope of Explanation |
|---|---|---|---|
| 2026 · PMID 42810372 | Randomized Double-Blind Placebo-Controlled Phase III in Humans; TRIUMPH-2 | Obesity combined with type 2 diabetes patients showed improved weight and blood glucose control at 80 weeks. | Experimental Medication and Specific Inclusion Criteria; Cannot Be Converted into Commercial Use Commitment. |
| 2026 · PMID 42814954 | Human randomized, double-blind Phase III; TRIUMPH-1 | Obese adults experienced significant weight loss; Certain knee osteoarthritis and sleep apnea subgroups also showed improvement. | Some OSA papers share the mother trials, so they cannot be considered as fully independent replication. |
| 2025 · PMID 40609566 | Adults with type 2 diabetes; Retatrutide Phase II DXA body composition sub-study | Some study dose groups showed total fat reduction better than placebo, supplementing evidence of body composition beyond weight. | Not every dose shows significant effects; only some subjects completed pre- and post-DXA, so it cannot be considered pure fat loss without lean mass loss. |
| 2023 · PMID 37366315 | 338 overweight or obese adults; 48-week randomized double-blind Phase II trial | Retatrutide weight loss in all study dose groups was superior to placebo, with the highest dose group showing an average decrease of 24.2% at 48 weeks. | Dose exploration trial showed gastrointestinal reactions and heart rate changes; not individual effects or bottle dose recommendations. |
References
What findings emerged from weight studies in populations with diabetes?
Obesity combined with type 2 diabetes patients showed improved weight and blood glucose control at 80 weeks.[1] ↗
Randomized Double-Blind Placebo-Controlled Phase III in Humans; TRIUMPH-2
Experimental Medication and Specific Inclusion Criteria; Cannot Be Converted into Commercial Use Commitment.
View the Article Title and Full Citation＋
Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.
Lancet (London, England) · Volume, issue, year 2026
First published 2026-09-29 · PMID 42810372
DOI 10.1016/S0140-6736(26)01861-1
What was observed in phase III obesity studies?
Obese adults experienced significant weight loss; Certain knee osteoarthritis and sleep apnea subgroups also showed improvement.[2] ↗
Human randomized, double-blind Phase III; TRIUMPH-1
Some OSA papers share the mother trials, so they cannot be considered as fully independent replication.
View the Article Title and Full Citation＋
Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.
The New England Journal of Medicine · Volume, Issue, Year 2026
First published 2026-09-29 · PMID 42814954
DOI 10.1056/NEJMoa2604169
What does DXA body composition analysis supplement?
Some study dose groups showed total fat reduction better than placebo, supplementing evidence of body composition beyond weight.[3] ↗
Adults with type 2 diabetes; Retatrutide Phase II DXA body composition sub-study
Not every dose shows significant effects; only some subjects completed pre- and post-DXA, so it cannot be considered pure fat loss without lean mass loss.
View the Article Title and Full Citation＋
Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.
The Lancet. Diabetes & Endocrinology · Volume and issue year 2025
First published 2025-06-30 · PMID 40609566
DOI 10.1016/S2213-8587(25)00092-0
How much weight loss was shown in early dose exploration?
Retatrutide weight loss in all study dose groups was superior to placebo, with the highest dose group showing an average decrease of 24.2% at 48 weeks.[4] ↗
338 overweight or obese adults; 48-week randomized double-blind Phase II trial
Dose exploration trial showed gastrointestinal reactions and heart rate changes; not individual effects or bottle dose recommendations.
View the Article Title and Full Citation＋
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
The New England Journal of Medicine · Volume, Issue, Year 2023
First published 2023-06-26 · PMID 37366315
DOI 10.1056/NEJMoa2301972
Common issues and corresponding evidence
What research findings exist for Retatrutide in obesity and weight loss?＋
Obesity combined with type 2 diabetes patients showed improvement in weight and blood glucose control at 80 weeks. Other studies reported significant weight loss in obese adults; Specific knee osteoarthritis and sleep apnea subgroups also showed improvement.[1] ↗ [2] ↗
Has Retatrutide been directly studied for fat mass?＋
Yes. DXA sub-studies in type 2 diabetes populations showed that some dose groups had more pronounced reductions in total fat; this is a body composition sub-study in a specific population and cannot be used to promise complete preservation of lean body mass.[3] ↗
Retatrutide—these conclusions apply to which study populations?＋
Human randomized, double-blind, placebo-controlled Phase III; TRIUMPH-2； Randomized, double-blind, Phase III human trial; TRIUMPH-1； Adults with type 2 diabetes; Retatrutide Phase II DXA body component study. Investigational drug and specific inclusion criteria; No conversion to commercial use commitment.[1] ↗ [2] ↗ [3] ↗
Retatrutide
Return to catalog specifications and batch file verification entry.
